BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24462804)

  • 1. Transitional cell carcinoma of the ovary: a case-control study.
    Guseh SH; Rauh-Hain JA; Tambouret RH; Davis M; Clark RM; Boruta DM; Goodman A; Growdon WB; Schorge JO; del Carmen MG
    Gynecol Oncol; 2014 Mar; 132(3):649-53. PubMed ID: 24462804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan.
    Chao KC; Chen YJ; Juang CM; Lau HY; Wen KC; Sung PL; Fang FY; Twu NF; Yen MS
    Taiwan J Obstet Gynecol; 2013 Mar; 52(1):81-4. PubMed ID: 23548224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinosarcoma of the ovary: a case-control study.
    Rauh-Hain JA; Growdon WB; Rodriguez N; Goodman AK; Boruta DM; Schorge JO; Horowitz NS; del Carmen MG
    Gynecol Oncol; 2011 Jun; 121(3):477-81. PubMed ID: 21420726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.
    Davis M; Rauh-Hain JA; Andrade C; Boruta DM; Schorge JO; Horowitz NS; May T; del Carmen MG
    Gynecol Oncol; 2014 Mar; 132(3):760-6. PubMed ID: 24440832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.
    Kommoss F; Kommoss S; Schmidt D; Trunk MJ; Pfisterer J; du Bois A;
    Gynecol Oncol; 2005 Apr; 97(1):195-9. PubMed ID: 15790458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma.
    Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K
    J Surg Oncol; 2006 Apr; 93(5):379-86. PubMed ID: 16550573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
    Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
    Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
    Bristow RE; Duska LR; Montz FJ
    Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
    Rauh-Hain JA; Diver EJ; Clemmer JT; Bradford LS; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
    Gynecol Oncol; 2013 Oct; 131(1):46-51. PubMed ID: 23906658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?
    Perri T; Ben-Baruch G; Kalfon S; Beiner ME; Helpman L; Hogen LB; Shapira-Frommer R; Korach J
    Gynecol Oncol; 2013 Oct; 131(1):27-31. PubMed ID: 23880152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma.
    Ben-Baruch G; Sivan E; Moran O; Rizel S; Menczer J; Seidman DS
    Gynecol Oncol; 1996 Mar; 60(3):393-6. PubMed ID: 8774644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
    Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
    Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.